Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A1 | P22736 | 1/20 | 0.60 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.60 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | CDC25B | P30305 | 1/20 | 0.49 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.48 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.47 |
| ▸ | KDM6B | O15054 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29702097 | 1.00 | NR4A1 (0.60) | NR4A1NR4A2NR4A3KDM4EMAPKAPK2 | |
| Water SCHEMBL5659378 | 0.98 | NR4A1 (0.58) | NR4A1NR4A2NR4A3KDM4EMAPKAPK2 | |
| SCHEMBL27598089 | 0.87 | KDM4E (0.58) | KDM4EMAPKAPK2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL15129900 | 0.86 | NR4A1 (0.49) | NR4A1NR4A2NR4A3KDM4EMAPKAPK2 | |
| SCHEMBL3837108 | 0.86 | KDM4E (0.53) | NR4A1NR4A2NR4A3KDM4EMAPKAPK2 | |
| SCHEMBL2223329 | 0.85 | NR4A1 (0.60) | NR4A1NR4A2NR4A3KDM4EMAPKAPK2 | |
| SCHEMBL31522172 | 0.85 | NR4A1 (0.60) | NR4A1NR4A2NR4A3KDM4EMAPKAPK2 | |
| SCHEMBL2380673 | 0.84 | MCL1 (0.49) | NR4A1NR4A2NR4A3KDM4EMAPKAPK2 | |
| SCHEMBL1828133 | 0.84 | KDM4E (0.55) | KDM4EMAPKAPK2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL17040876 | 0.84 | KDM4E (0.55) | KDM4EMAPKAPK2CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119591645-A | Isoquinoline-5-formic acid coordinated catalyst, composite catalyst, preparation method and application | 上海元革新材料科技有限公司 | 2025-03-11 | — | — | CN | claimed |
| CN-111995575-A | Preparation method of quinoline amide compound | 河南农业大学 | 2020-11-27 | — | — | CN | claimed |
| US-8288435-B2 | 2-aza-bicyclo[3.1.0]hexane derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-10-16 | — | — | US | claimed |
| EP-2094690-A2 | 2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2009-09-02 | — | — | EP | claimed |
| WO-2008081399-A2 | 2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-07-10 | — | — | WO | claimed |
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| EP-3856178-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-11 | — | — | EP | disclosed |
| CN-119591645-A | Isoquinoline-5-formic acid coordinated catalyst, composite catalyst, preparation method and application | 上海元革新材料科技有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-113164459-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-03 | — | — | CN | disclosed |
| WO-2024145483-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND METHODS OF MAKING AND USING THE SAME | HTG MOLECULAR DIAGNOSTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| WO-2024112201-A1 | DNA GYRASE INHIBITORS | UNIVERSITEIT LEIDEN (NL) | 2024-05-30 | — | — | WO | disclosed |
| CN-116396412-B | Novel quinoline/isoquinoline quaternary ammonium salt modified chitosan and preparation method and application thereof | 河南驼人康君抗菌科技有限公司 | 2024-02-27 | — | — | CN | disclosed |
| US-5827859-A | ADMINISTERED TO TREAT AIDS; VIRICIDES | AGOURON PHARMACEUTICALS, INC. | 1998-10-27 | — | — | US | disclosed |
| US-5824688-A | HIV protease inhibitors | AGOURON PHARMACEUTICALS, INC. | 1998-10-20 | — | — | US | disclosed |
| EP-0802916-A1 | LOW MOLECULAR WEIGHT BICYCLIC THROMBIN INHIBITORS | BIOCHEM PHARMA INC (CA) | 1997-10-29 | — | — | EP | disclosed |
| EP-0722439-A1 | HIV PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1996-07-24 | — | — | EP | disclosed |
| US-5484926-A | VIRICIDES AND ENZYME INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1996-01-16 | — | — | US | disclosed |
| WO-1995009843-A1 | HIV PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1995-04-13 | — | — | WO | disclosed |
| US-4396619-A | ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1983-08-02 | — | — | US | disclosed |
| US-4382932-A | Isoquinolinium substituted cephalosporins | ELI LILLY AND COMPANY (US) | 1983-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | NR4A1 722/4885NR4A2 1245/4885NR4A3 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.